S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. - GALT|
|Hagens Berman Reminds Investors in Galectin Therapeutics, Inc. of the Sept. 29, 2014 Lead Plaintiff Class-Action Deadline|
|SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Galectin Therapeutics Inc. to Contact Brower Piven Before the September 29, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- GALT|
|EQUITY ALERT: Rosen Law Firm Reminds Galectin Therapeutics, Inc. Investors of Important September 29, 2014 Class Action Deadline -- GALT|
|SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT|
|Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development|
|Galectin Therapeutics to Present at Aegis Capital Corporation 2014 Healthcare and Technology Conference|
|Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company's Development Program|
|Galectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference|
|Galectin Therapeutics Announces Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy|
Click above to view more mutual fund data and stats for galt - Galectin Therapeutics Inc.